目的本研究通过分析乳腺肿物的自动乳腺全容积扫描(automated breast volume scanner,ABVS)冠状面声像图特点,初步探讨ABVS冠状面征象“云雾征”对乳腺占位性病变的鉴别诊断及预后评估价值。方法本文为横断面研究。收集2020年1月至2021...目的本研究通过分析乳腺肿物的自动乳腺全容积扫描(automated breast volume scanner,ABVS)冠状面声像图特点,初步探讨ABVS冠状面征象“云雾征”对乳腺占位性病变的鉴别诊断及预后评估价值。方法本文为横断面研究。收集2020年1月至2021年1月在广州医科大学附属第三医院就诊的经ABVS扫查,乳腺影像报告和数据系统(BI-RADS)分类在3类以上,且经过手术病理证实的乳腺肿物共154例。通过回顾性分析乳腺肿物是否出现“云雾征”及“汇聚征”,分别比较“云雾征”与患者年龄、肿物大小、肿物良恶性、是否为浸润性及淋巴结转移之间的相关性,使用χ^(2)检验进行统计分析,对比冠状面“云雾征”及“汇聚征”对乳腺占位性病变诊断的灵敏度、特异度、准确度。结果本研究一共纳入乳腺肿物154个,包括良性病变42个,年龄(40.5±10.9)岁,肿物长径(26.7±13.7)mm;恶性病变112个,年龄(55.4±11.4)岁,肿物长径(17.9±11.5)mm。“云雾征”出现率在不同年龄组、不同肿物长径组间差异均有统计学意义(P<0.001、P=0.013);“云雾征”出现率在良性肿物组和恶性肿物组之间差异有统计学意义[14.3%(6/42)比75.0%(84/112)](P<0.001)。“云雾征”对肿物良恶性诊断的灵敏度、特异度、准确度分为85.7%、75.0%、77.9%。“云雾征”的出现与雌、孕激素受体(ER、PR)表达阳性与否存在相关(P=0.049、0.005),但与Ki-67、Cerb-B2及淋巴结转移没有明显相关性(P=0.649、1.000、0.064)。本组“汇聚征”诊断乳腺癌的灵敏度、特异度、准确度为43.8%、90.5%、56.4%。结论“云雾征”对乳腺占位性病变的良恶性鉴别及预测ER、PR表达的判断具有一定价值。展开更多
Objective: The combination of highly active antiretroviral therapy (HAART) and chemotherapy with ABV regimen (doxorubicin, bleomycin and vincristine) is a promising approach for the treatment of advanced HIV-related K...Objective: The combination of highly active antiretroviral therapy (HAART) and chemotherapy with ABV regimen (doxorubicin, bleomycin and vincristine) is a promising approach for the treatment of advanced HIV-related Kaposi's sarcoma (KS). Here we analyzed the relationship between the CD4 lymphocyte cell count and the clinical response to chemotherapy. Methods: The 176 HIV infected patients with advanced KS who failed to respond to prior HAART were selected. All these patients were then preceded to chemotherapy with ABV regimen which was administered at 3 weekly intervals for 6 cycles. For each patient CD4 cell count was done before starting chemotherapy and after finishing 6 cycles of chemotherapy. The difference of CD4 cell counts pre chemotherapy and post chemotherapy was compared with the clinical progress of the patients after 6 cycles of chemotherapy. Results: The overall clinical remission was shown in 93.7% patients. Progressive disease (PD) and no change in clinical condition (NC) was shown in 6.3% patients. The increase in CD4 cell count post chemotherapy was found in 89.8% patients and the decrease in CD4 cell count was seen in 10.2% patients. The difference of the mean CD4 cell counts for patients in group CR + PR (complete relief + partial relief) before and after chemotherapy was highly significant. The difference of the mean CD4 cell counts for patients in group NC + PD before and after chemotherapy was not significant. The difference in CD4 cell counts in CR + PR and NC + PD groups before and after chemotherapy was highly significant. Conclusion: The HIV related KS patients on HAART benefit from the chemotherapy as it increases the CD4 cell count and it has positive impact on clinical remission of KS.展开更多
文摘目的本研究通过分析乳腺肿物的自动乳腺全容积扫描(automated breast volume scanner,ABVS)冠状面声像图特点,初步探讨ABVS冠状面征象“云雾征”对乳腺占位性病变的鉴别诊断及预后评估价值。方法本文为横断面研究。收集2020年1月至2021年1月在广州医科大学附属第三医院就诊的经ABVS扫查,乳腺影像报告和数据系统(BI-RADS)分类在3类以上,且经过手术病理证实的乳腺肿物共154例。通过回顾性分析乳腺肿物是否出现“云雾征”及“汇聚征”,分别比较“云雾征”与患者年龄、肿物大小、肿物良恶性、是否为浸润性及淋巴结转移之间的相关性,使用χ^(2)检验进行统计分析,对比冠状面“云雾征”及“汇聚征”对乳腺占位性病变诊断的灵敏度、特异度、准确度。结果本研究一共纳入乳腺肿物154个,包括良性病变42个,年龄(40.5±10.9)岁,肿物长径(26.7±13.7)mm;恶性病变112个,年龄(55.4±11.4)岁,肿物长径(17.9±11.5)mm。“云雾征”出现率在不同年龄组、不同肿物长径组间差异均有统计学意义(P<0.001、P=0.013);“云雾征”出现率在良性肿物组和恶性肿物组之间差异有统计学意义[14.3%(6/42)比75.0%(84/112)](P<0.001)。“云雾征”对肿物良恶性诊断的灵敏度、特异度、准确度分为85.7%、75.0%、77.9%。“云雾征”的出现与雌、孕激素受体(ER、PR)表达阳性与否存在相关(P=0.049、0.005),但与Ki-67、Cerb-B2及淋巴结转移没有明显相关性(P=0.649、1.000、0.064)。本组“汇聚征”诊断乳腺癌的灵敏度、特异度、准确度为43.8%、90.5%、56.4%。结论“云雾征”对乳腺占位性病变的良恶性鉴别及预测ER、PR表达的判断具有一定价值。
文摘Objective: The combination of highly active antiretroviral therapy (HAART) and chemotherapy with ABV regimen (doxorubicin, bleomycin and vincristine) is a promising approach for the treatment of advanced HIV-related Kaposi's sarcoma (KS). Here we analyzed the relationship between the CD4 lymphocyte cell count and the clinical response to chemotherapy. Methods: The 176 HIV infected patients with advanced KS who failed to respond to prior HAART were selected. All these patients were then preceded to chemotherapy with ABV regimen which was administered at 3 weekly intervals for 6 cycles. For each patient CD4 cell count was done before starting chemotherapy and after finishing 6 cycles of chemotherapy. The difference of CD4 cell counts pre chemotherapy and post chemotherapy was compared with the clinical progress of the patients after 6 cycles of chemotherapy. Results: The overall clinical remission was shown in 93.7% patients. Progressive disease (PD) and no change in clinical condition (NC) was shown in 6.3% patients. The increase in CD4 cell count post chemotherapy was found in 89.8% patients and the decrease in CD4 cell count was seen in 10.2% patients. The difference of the mean CD4 cell counts for patients in group CR + PR (complete relief + partial relief) before and after chemotherapy was highly significant. The difference of the mean CD4 cell counts for patients in group NC + PD before and after chemotherapy was not significant. The difference in CD4 cell counts in CR + PR and NC + PD groups before and after chemotherapy was highly significant. Conclusion: The HIV related KS patients on HAART benefit from the chemotherapy as it increases the CD4 cell count and it has positive impact on clinical remission of KS.
